Outsourcing a clinical trial completely or partially 2022| ��ƽ��

Likelihood over past two years of outsourcing a clinical trial completely or partially among biopharmaceutical companies worldwide as of 2022

Characteristic	More likely	No change	Less likely
All of a trial	35%	55%	10%
Portion of a trial	47%	49%	4%

Download

Source

Show detailed source information?

Already a member?

Sources

Release date

September 2022

More information

Region

Worldwide

Survey time period

April 2022

Number of respondents

152 executives

Method of interview

Panel survey

Supplementary notes

The surveyed are working for pharma, biopharma, or biotech companies; they have drug development decision-making responsibility and are director-level or above; they work in a role related to drug development; their companies have at least one compound in development; they are from the US/Canada, Europe, Asia, Australia, or Middle East/India.

Original question: "Over the past two years, has your company become more or less likely to outsource all of a trial?" (n=115, respondents not recently involved with outsourcing excluded)
Original question: "Over the past two years, has your company become more or less likely to outsource a portion of a trial?" (n=115, respondents not recently involved with outsourcing excluded)

Citation formats

According to a survey conducted in 2022, almost half of biopharma executives stated that over the past two years it had become more likely that their company outsources a portion of a clinical trial. This statistic describes the change in likelihood over the past two years of outsourcing a clinical trial completely or partially among biopharmaceutical companies around the world.